These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20141428)

  • 1. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
    Alousi AM; Uberti J; Ratanatharathorn V
    Leuk Lymphoma; 2010 Mar; 51(3):376-89. PubMed ID: 20141428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.
    Kim SJ; Won JH
    Leuk Lymphoma; 2012 Jan; 53(1):19-25. PubMed ID: 21740304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
    Kharfan-Dabaja MA; Bazarbachi A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for prevention and treatment of graft-versus-host disease.
    Kharfan-Dabaja MA; Cutler CS
    Int J Hematol; 2011 May; 93(5):578-585. PubMed ID: 21547615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
    Arai S; Sahaf B; Narasimhan B; Chen GL; Jones CD; Lowsky R; Shizuru JA; Johnston LJ; Laport GG; Weng WK; Benjamin JE; Schaenman J; Brown J; Ramirez J; Zehnder JL; Negrin RS; Miklos DB
    Blood; 2012 Jun; 119(25):6145-54. PubMed ID: 22563089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cells in chronic graft-versus-host disease.
    Sarantopoulos S; Blazar BR; Cutler C; Ritz J
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):16-23. PubMed ID: 25452031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.
    Crocchiolo R; Castagna L; El-Cheikh J; Helvig A; Fürst S; Faucher C; Vazquez A; Granata A; Coso D; Bouabdallah R; Blaise D
    Exp Hematol; 2011 Sep; 39(9):892-6. PubMed ID: 21703987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D
    BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab.
    Kennedy VE; Sahaf B; Wu F; Ehlinger ZJ; Arai S; Miklos DB
    Transplant Cell Ther; 2024 May; 30(5):518.e1-518.e13. PubMed ID: 38458479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
    van Dorp S; Pietersma F; Wölfl M; Verdonck LF; Petersen EJ; Lokhorst HM; Martens E; Theobald M; van Baarle D; Meijer E; Kuball J
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):671-8. PubMed ID: 19450751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.
    Van Hoef ME
    Haematologica; 2013 Apr; 98(4):e40-1. PubMed ID: 23543154
    [No Abstract]   [Full Text] [Related]  

  • 17. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
    Xhaard A; Hermet E; Bay JO; Peffault de Latour R
    Bull Cancer; 2011 Aug; 98(8):889-99. PubMed ID: 21835730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in hematopoietic cell transplantation.
    Arai S; Miklos DB
    Expert Opin Biol Ther; 2010 Jun; 10(6):971-82. PubMed ID: 20420511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.